{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-042675","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.118753+00:00","generated_at":"2026-06-29T18:55:52.632319+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech","bullets":["Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.","GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.","Core (NGS) revenue grew 296% YoY to $25.7M.","Acquisition of CSI Laboratories (cancer diagnostics) and commercial agreement with Helio Health via strategic investment.","Incremental controlling investment in Chinese JV FF Gene Biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-042675","json":"https://secwatch.observer/filing/0001564590-21-042675.json","markdown":"https://secwatch.observer/filing/0001564590-21-042675.md","text":"https://secwatch.observer/filing/0001564590-21-042675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/0001564590-21-042675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/flgt-8k_20210809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:55:52.632319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}